ReviewJournal of diabetes and metabolic disorders2026
Metabolic memory in diabetes: decoding the molecular basis of persistent cellular programming for next-generation therapeutic strategies.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic complications often progress despite successful normalization of blood glucose and glycated hemoglobin (HbA1c), highlighting a major limitation of current glucose-centered therapeutic strategies. Although metabolic memory has traditionally been attributed to epigenetic alterations or oxidative stress, these mechanisms alone cannot adequately explain the persistence, tissue specificity, and progressive nature of diabetic complications. This review introduces Persistent Cellular Programming (PCP) as a novel systems-level conceptual framework that redefines metabolic memory as a stable pathological cellular state maintained by coordinated interactions among metabolic remodeling, epigenetic regulation, protein post-translational modifications, non-coding RNAs, mitochondrial dysfunction, organelle crosstalk, redox imbalance, immune reprogramming, and transcriptional network stabilization. Rather than functioning independently, these regulatory layers establish self-reinforcing molecular circuits that preserve pathological cellular phenotypes long after restoration of normoglycemia. The review critically evaluates how metabolic rewiring, inter-organelle communication, and tissue-specific cellular plasticity collectively sustain diabetic complications and examines why conventional single-target therapies frequently fail to reverse these integrated networks. Major knowledge gaps are identified, including the reversibility of persistent cellular programming, the role of mitochondrial inheritance and organelle communication, and the absence of clinically validated biomarkers to quantify cellular memory. Finally, we propose a next-generation therapeutic paradigm that shifts the focus from glucose lowering to network medicine, precision therapeutics, digital biomarkers, and personalized cellular reprogramming, providing a conceptual foundation for achieving durable disease modification rather than temporary metabolic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.